Introduction
Strategies for investing in drug development and commercialization
Major breakthroughs in healthcare – from cell and gene therapies (CGT) to mRNA vaccines – have highlighted the power and value of investing in biopharma innovation. CGT alone could be worth US$80 billion by 2029. However, in an industry where an estimated 90% of clinical drug development fails, biotech firms and start-ups need to stand out from the competition to appeal to investors looking for a solid return on investment.
There are deals to be done for biotech firms with the right therapeutic innovations. Big pharma companies are eyeing emerging start-ups as they seek to replenish their drugs pipeline before exclusivity rights on top-selling products expire. Investment firms are also looking to fill gaps in their portfolios. In the US, investor sentiment is improving because of a rebound in stock prices, expectations of a cut in interest rates and a boom in mergers and acquisitions in the sector. However, investors remain cautious about backing earlier stage and riskier companies.
The Financial Times, in partnership with Syneos Health, is bringing together investors, biotechs and big pharma for part two of the Funding Biopharma Innovation series. Join us in person in New York or online as we explore how to create the competitive advantage that enables emerging biotechs to stand out from their peers. Gain insights into the innovative strategies being adopted by biotechs to increase the probability of successful drug development and commercial uptake; and learn how investors in biotechs are achieving positive returns.